| International Session（Symposium）3(JSGE・JGES・JSGS・JSGCS) |
| Thu. November 5th 14:00 - 17:00 Room 11: Portopia Hotel South Wing Topaz |
| Regenerative medicine for the treatment of inflammatory bowel disease. | |||
| Ryuichi Okamoto1,2, Mamoru Watanabe3 | |||
| 1Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), 2Center for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), 3Tokyo Medical and Dental University | |||
|
|||
|
|||
| Treatment of inflammatory bowel disease (IBD) has dramatically improved in the past decades, especially by using biologic agents such as anti-TNF-α antibodies. As a result of improvement, the primary goal of treatment has been set to a higher standard, which requires both the improvement of the clinical symptoms and the achievement of “mucosal healing,” to guarantee long-term remission of IBD patients. However, a particular population of refractory patients fails to achieve mucosal healing, resulting in poor prognosis. Therefore, the development of a novel therapy that can promote intestinal mucosal regeneration is required. Recent advances in intestinal stem cell (ISC) biology have made it possible to maintain and expand mice ISCs in vitro. Also, we can culture human ISCs in ex-vivo environments, from a few pieces of endoscopic biopsy specimens. Animal studies provide evidence that these in vitro-cultured human ISCs are a robust resource of regenerative therapy that may be applied to treat refractory ulcers of IBD patients. In the present talk, we would like to introduce the regenerative therapy concepts that are currently under development and further discuss its use in the treatment of IBD |
|||
|
Index Term 1: Organoid Index Term 2: Regenerative Medicine |
|||
| Page Top | |||